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Synthesis biological evaluation and SAR study of novel pyrazole 
analogues as inhibitors of Mycobacterium tuberculosis: Part 2. 
Synthesis of rigid pyrazolones.  
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Abstract – Two series of novel rigid pyrazolone derivatives were synthesized and evaluated as 
inhibitors of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis. Two of these 
compounds showed high activity against MTB (MIC = 4 μg/mL). The newly synthesized 
pyrazolones were also computationally investigated to analyze their fit properties to the 
pharmacophoric model for antitubercular compounds previously built by us. Results are in 
agreement with that previously found by us for a class of pyrazole analogues and confirm the 
fundamental role of the p-chlorophenyl moiety at C4 for the antimycobacterial activity. 
 
1. Introduction 
On 2008 falled the 125th anniversary of Robert Koch’s discovery of the bacillus Mycobacterium 
tuberculosis (MTB),
1
 the etiological agent of the well known respiratory disease Tuberculosis (TB). 
Despite MTB was identified more than one century ago and many efficient drugs were discovered 
during this time to eradicate the disease, TB still remains one of the leading cause of worldwide 
illness and death. About 9.2 million new cases and 1.7 million deaths from TB occurred in 2006, of 
which 0.7 million cases and 0.2 million deaths were in HIV-positive people.
2
 Moreover the 
emergence of multiple drug resistant (MDR-TB) strains and, more recently, extensively drug 
resistant (XDR-TB) strains makes the discovery and the development of new drugs a priority.
3
  
In the last years, our work was focused into the discovery and the synthesis of new  
antimycobacterial compounds having pyrazole structure. Computational as well as synthetic studies 
led us to identify pyrazoles 1-4 as the best hit compounds with MIC values ranging between 4 and 
12 g/mL (Figure 1).4-5 Structure-activity realtionship (SAR) studies revealed that the presence of 
the p-chlorobenzoyl moiety at the C4 of the pyrazole ring of 1-4 is fundamental for the 
antimycobacterial activity of these compounds. These pyrazoles bearing a benzoyl moiety at C4 
exist under certain conditions
6
 in one or more tautomeric forms and also in an hydrogen bond 
stabilized form (Structure A, Figure 1). In particular, an in-depth investigation by Holzer and co-
workers revealed that 5-hydroxypyrazoles such as 1-4 might exist in the chelated form A, because 
of the stabilization by intramolecular hydrogen bond which prevents the free rotation of C4-C6 
bond.
6
 On this basis, we assumed that the antimycobacterial activity of  1-4 could be partly related 
to the constrained conformation A where the p-Cl-phenyl ring is fixed in a “syn” relative position 
with respect to the C3-methyl group. Accordingly, we planned the synthesis of a series of 
pyrazolones with general structure B and C (Figure 1). Pyrazolones B could be considered as rigid 
derivatives of pyrazoles 1-4 with a “syn” conformation. The introduction of secondary amine 
moieties on pyrazolones B and C was settled on the basis of recent results on the synthesis of 
antimycobaterial pyrrole compounds.
7
 It is known that the thiomorpholine or N-methylpiperazine 
moieties on pyrrole derivatives, such as the active BM212, play a crucial role in the inhibition of 
MTB. Hence, the intrduction of a secondary amine coud play a dual role, leading to compounds 
with constrained conformation and with a potential improvement of their antimycobacterial activity. 
Finally, the synthesis of a series of pyrazolones having general structure C was planned to support 
the hypothesis that the p-chlorophenyl moiety at C4 could have a fundamental role for the 
antimycobacterial activity. 
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Figure 1. Pyrazoles and pyrazolones derivatives 
 
2. Chemistry 
We first focused our attention on the synthesis of derivatives with general structure B. Pyrazoles 1 
and 3, chosen as synthetic precursors, were synthesized according to reported procedures.
4-5
 
Reaction of 1 and 3 with different secondary amines led to desired pyrazolones 5a-k. The reactions 
were performed  in DMF or DME under microwave irradiation at 160 °C and were completed in 
only 10 minutes (Scheme 1). 
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Scheme 1. Reagents and conditions: i. Secondary amines (1.2 eq), DMF (for 5a-h) or DME (for 5i-
k), W, 160 °C, 10 min. 
 
A second series of pyrazolone derivatives with general structure C was synthesized. Commercially 
available pyrazolone 6 was reacted under the Vilsmeir conditions with POCl3 in DMF at 80 °C. 
When the reaction was stopped with NaOH 30% solution, 7 was isolated as the only product. On 
the other hand, when Vilsmeir reaction was quenched with distilled H2O and stirred in aqueous 
medium for 48 h, desired aldehyde 8 was obtained in 92 % yield. Aldehyde 8 was then reacted with 
several secondary amines at 100 °C under microwave irradiation affording desired compounds 9a-g 
in good yields (Scheme 2). Stereochemistry of 5a-k and 9a-g was determined by NOESY 
experiments. NOE-cross couplings are illustrated in Figure 2. 
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Scheme 2. Reagents and conditions: i. a) POCl3, DMF, 2 h, 80 °C then b) H2O, rt, 48 h. ii. a) 
POCl3, DMF, 2 h, 80 °C then b) NaOH 30%. iii. R1R2NH, W, 100 °C, 5 min. 
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Figure 2. Observed NOE cross-couplings 
 
3. Results and discussion. 
Componds 5a-k, 7 and 9a-g were assayed for their inhibitory activity toward M. tuberculosis 
H37Rv (ATCC27294). The minimum inhibitory concentration (MIC expressed as g mL-1) was 
determined for each compound. Resulting data were reported in Table 1. 
 
Table 1. Schematic representation and MIC values for 5, 7 and 9. 
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Compound R R1 
MIC (g mL-1) 
M. tuberculosis 
5a H thiomorpholine 8 
5b H N-Me-piperazine 8 
5c H morpholine 16 
5d H N(Me)2 32 
5e Cl thiomorpholine 8 
5f Cl N-Me-piperazine 4 
5g Cl morpholine 4 
5h Cl N(Me)2 16 
5i Cl piperidine >64 
5j Cl 4-Me-piperidine 64 
5k Cl PrNMe 64 
7 Cl  >64 
9a Cl N-Ph-piperazine 64 
9b Cl N-Me-piperazine 64 
9c Cl morpholine 64 
9d Cl N-Ac-piperazine 64 
9e Cl NH-Ph 64 
9f Cl N-(2-hydroxyethyl)-piperazine 64 
9g Cl N-(2-furoyl)-piperazine 32 
 
 
The presence of a chlorine atom on the N1-phenyl ring (5e-h) caused an improvement of activity 
with respect to non-halogenated 5a-d. In particular, 5f-g, bearing N-Me-piperazine and morpholine 
moieties proved to be very active with MIC = 4 g/mL. On the other hand, the presence of a 
piperidine or Me-piperidine moieties (5i-k) resulted to be detrimental for activity. This result 
suggests the relevant role of an additional heteroatom on the cycloalkyl amine ring. Compounds 9a-
g resulted inactive against MTB. On the basis of these latter biological data, it seems evident that 
the p-chlorophenyl ring is crucial for antimycobacterial activity. 
The cytotoxicity of compounds 5a-k, 7 and 9a-g toward VERO cells was also assayed. The active 
compounds 5a-b and 5e-f showed significant cytoxicity (CC50 = 5.71 g/mL for 5a, 5.58 g/mL for 
5b, 4.86 g/mL for 5e, 5.49 g/mL for 5f). The active compound 5g showed a slightly better 
cytotoxic profile with CC50 = 13.29 g/mL. On the contrary the inactive compounds 9a-g proved to 
be no cytotoxic with CC50 > 125 g/mL. 
 
4. Computational studies. 
The new pyrazolone derivatives were analyzed for their ability to fit a pharmacophoric model for 
antimycobacterial compounds, consisting in two hydrophobics, two aromatic ring features and a 
hydrogen bond acceptor group. Superposition of one of the most active compounds (5g) to the 
model (Figure 3A) showed a full complementarity between chemical groups of 5g and the 
pharmacophoric features. In fact, the RA1-HY1 system was matched by the p-chlorophenyl moiety 
at N1. The correspondence between the chlorine atom at R and HY1 accounted for the difference in 
activity found between R-chlorinated and unchlorinated analogues. In general, MIC values of 
chloro derivatives (5f-i) were better than those of the corresponding non halogenated analogues 5a-
d, lacking a group able to fit HY1. Moreover, the oxygen atom of the morpholine ring of 5g was the 
hydrogen bond acceptor group interacting with HBA. Also this contact was suggested to be very 
important for activity. In fact, compounds with a reduced ability (the thiomorpholino derivative 5e) 
or completely unable to fit HBA (5h-k) were all characterized by activity values lower that that 
found for 5f-g and 7, whose amino nitrogen atom is located at a ~2.8 Å distance from HBA. Finally, 
the additional p-chlorophenyl moiety at C4 matched RA2, while the methyl group at C3 was the 
hydrophobic group filling HY2.  
Superposition of compounds 9 to the model showed an interaction pattern similar to that found for 
compounds 5 (Figure 3B). However, the lack of the p-chlorophenyl moiety at C4 made such 
compounds unable to fit RA2, thus accounting for their low antimycobacterial activity. 
Such results were in agreement with that found by us for a class of pyrazole derivatives and 
suggesting that the p-chlorophenyl moiety at N1 was very important for activity, in addition to the 
ability of compounds to make a hydrogen bond contact coded by the HBA feature of the model. 
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Figure 3. Superposition of 5g (A) and 9a (B) into the model for antimycobacterial compounds. 
Pharmacophoric features are color coded: orange for aromatic rings (RA); green for hydrogen bond 
acceptor groups (HBA); cyan for hydrophobic regions (HY). The aromatic ring feature RA2 not 
mapped by 9a is in brown. 
 
5. Experimental 
Reagents were obtained from commercial suppliers and used without further purification. N,N-
dimethylformamide (DMF) and dimethoxyethane (DME) were purchased anhydrous (Aldrich), 
dichloromethane was dried over CaH2 prior to use. Anhydrous reactions were run under a positive 
pressure of dry N2. Merck silica gel 60 was used for flash chromatography (23–400 mesh). 
1
H NMR 
and 
13
C NMR spectra were measured at 200 MHz on a Bruker AC200F spectrometer and at 400 
MHz on a Bruker Avance DPX400. Chemical shifts were reported relative to CDCl3 at  7.24 ppm 
and to tetramethylsilane at  0.00 ppm.  
 
5.1. HPLC and MS analysis 
The purity of compounds was assessed by reverse-phase liquid chromatography and a mass 
spectrometer (Agilent series 1100 LC/ MSD) with a UV detector at k = 254 nm and with an 
electrospray ionization source (ESI). All the solvents were of HPLC grade (Fluka). Mass spectral 
(MS) data were obtained using an Agilent 1100 LC/ MSD VL system (G1946C) with a 0.4 mL/min 
flow rate using a binary solvent system of 95:5 methyl alcohol/water. UV detection was monitored 
at 254 nm. Mass spectra were acquired in positive mode scanning over the mass range of 50–1500. 
The following ion source parameters were used: drying gas flow, 9 mL/min; nebulize pressure, 40 
psig; drying gas temperature, 350 °C. 
 
5.2. Microwave irradiation experiments 
Microwave irradiation was conducted using a CEM Discover Synthesis Unit (CEM Corp., 
Matthews, NC). The machine consists of a continuous focused microwave power delivery system 
with operator selectable power output (0 to 300 W). The temperature of the contents of  the vessels 
was monitored using a calibrated infrared temperature sensor mounted under the reaction vessel. All 
experiments were performed using the stirring option whereby the contents of the vessels are stirred 
by means of rotating magnetic plate located below the floor of the microwave cavity and a Teflon-
coated magnetic stir bar in the vessel. 
 
5.3. Synthesis of pyrazolones 5a–k. 
Compounds 1 or 3 (1 eq./mol) were dissolved in anhydrous DMF or DME in a sealed vessel 
equipped with magnetic stirring bar. The appropriate amine was added (1.2 eq./mol) to the solution 
and the vessel placed in the microwave oven and heated  (160 °C , 10 min.) under microwave 
irradiation. After cooling, a saturated solution of NH4Cl was added and the aqueous phase was 
extracted with AcOEt (3x 10 mL). The combined organic layers were washed with a saturated 
solution of NH4Cl and H2O, dried over anhydrous Na2SO4, filtered and evaporated to dryness to 
afford crude compounds 5a–k, which were purified by flash chromatography (CH2Cl2/MeOH 99:1 
for compounds 5b, 5f, 5i-k; petroleum ether/ EtOAc 8:2 for compounds 5a, 5c, 5e, 5g) to afford the 
final products (25-70 % yield). 
5a: Yield: 70 %. 
1
H NMR (CDCl3):  (ppm) 7.91 (2H, d, J = 8.04 Hz, Ph), 7.44 (2H, d, J = 8.35 Hz, 
Ph), 7.32-7.28 (4H, m, Ph), 7.04 (1H, t, J = 7.30 Hz, Ph), 4.12 (2H, m, CH2NCH2), 3.55 (2H, m, 
CH2NCH2), 2.96 (2H, m, CH2SCH2), 2.64 (2H, m, CH2SCH2), 1.29 (3H, s, CH3). 
13
C NMR 
(CDCl3):  (ppm) 165.43, 161.66, 149.02, 139.40, 138.60, 133.70, 131.80, 131.60, 129.90, 129.50, 
129.20, 129.15, 124.10, 123.90, 119.20, 104.02, 57.73, 57.71, 28.81. MS: m/z  398-400 (M+1)
+
; 
420-422 (M+Na)
+;
 817-819.  Anal. for C21H20ClN3OS Calcd.%: C, 63.39; H, 5.07; N, 10,56; Found: 
C, 63.58; H, 5.08; N, 10.59. 
5b: Yield: 60 %. 
1
H NMR (CDCl3):  (ppm) 7.91 (2H, d, J = 7.71 Hz, Ph), 7.41 (2H, d, J = 7.52 Hz, 
Ph), 7.27-7.26 (4H, m, Ph), 7.01 (1H, t, J = 7.00 Hz, Ph), 3.92 (2H, m, CH2NCH2), 3.35 (2H, m, 
CH2NCH2), 2.65 (2H, m, CH2N(CH3)CH2), 2.43 (2H, m, CH2N(CH3)CH2), 2.27 (3H, s, NCH3), 
1.28 (3H, s, CH3). 
13
C NMR (CDCl3):  (ppm) 164.56, 161.81, 148.95, 139.52, 138.34, 133.54, 
131.80, 129.45, 128.74, 128.71, 128.67, 128.61, 128.57, 123.90, 119.31, 102.95, 55.96, 55.86,  
55.09, 51.10, 55.67, 15.81. MS: m/z  395-397 (M+1)
+
; 417-419 (M+Na)
+
; 433-435 (M+K)
+
, 811-
813 (2M+Na)
+
. Anal. for C22H23ClN4O Calcd.%: C, 66.91; H, 5.87; N, 14.19; Found: C, 67.11; H, 
5.71; N, 14.23. 
5c Yield: 30 %. 
1
H NMR (CDCl3):  (ppm) 7.95 (2H, d, J = 8.05 Hz, Ph), 7.48 (2H, d, J = 8.05 Hz, 
Ph), 7.36-7.32 (4H, m, Ph), 7.08 (1H, t, J = 7.30 Hz, Ph), 4.02 (2H, m, CH2OCH2), 3.96 (2H, m, 
CH2OCH2), 3.74 (2H, m, CH2NCH2), 3.38 (2H, m, CH2NCH2), 1.35 (3H, s, CH3). 
13
C NMR 
(CDCl3):  (ppm) 164.39, 161.74, 148.92, 139.44, 138.54, 133.16, 131.85, 129.60, 128.66, 124.02, 
119.29, 103.10, 67.68, 67.35, 55.60, 51.72, 15.83. MS: m/z  382-384 (M+1)
+
; 404-406 (M+Na)
+
; 
785-787 (2M+Na)
+
. Anal. for C21H20ClN3O2 Calcd.%: C, 66.05; H, 5.28; N, 11; Found: C, 66.76; 
H, 5.30; N, 11.04. 
5d: Yield: 25 %. 
1
H NMR (CDCl3):  (ppm) 8.01 (2H, d, J = 8.04 Hz, Ph), 7.48 (2H, d, J = 8.04 Hz, 
Ph), 7.37-7.34 (4H, m, Ph), 7.09 (1H, t, J = 7.29 Hz, Ph), 3.58 (3H, s, CH3NCH3), 3.08 (3H, s, 
CH3NCH3), 1.37 (3H, s, CH3). 
13
C NMR (CDCl3):  (ppm) 165.64, 162.00, 148.51, 139.65, 138.32, 
133.45, 131.96, 129.37, 128.60, 123.76, 119.12, 102.44, 46.76, 43.51, 15.69.  MS: m/z  340-342 
(M+1)
+
; 362-364 (M+Na)
+
; 701-703 (2M+Na)
+
. Anal. for C19H18ClN3O  Calcd.%: C, 67.15; H, 
5.34; N, 12.37; Found: C, 67.28; H, 5.35; N, 12.39. 
5e: Yield: 50 %. 
1
H NMR (CDCl3):  (ppm) 7.91 (2H, d, J = 8.53 Hz, Ph), 7.44 (2H, d, J = 8.53 Hz, 
Ph), 7.29-7.23 (4H, m, Ph), 4.10 (2H, m, CH2NCH2), 3.55 (2H, m, CH2NCH2), 2.95 (2H, m, 
CH2SCH2), 2.63 (2H, m, CH2SCH2), 1.27 (3H, s, CH3). 
13
C NMR (CDCl3):  (ppm) 165.67, 
161.61, 149.41, 138.71, 138.06, 133.57, 132.21, 132.12, 131.80, 130.05, 129.75, 129.65, 129.19, 
128.83, 120.05, 103.77, 57.76, 53.78, 28.66. MS: m/z  432-434 (M+1)
+
; 454-456 (M+Na)
+ 
; 470-
472 (M+K)
+ 
; 887-885 (2M+Na)
+
. Anal. for C21H19Cl2N3OS Calcd.%: C, 58.34; H, 4.43; N, 9.72; 
Found: C, 58.46; H, 4.44; N, 9.74. 
5f: Yield: 50 %. 
1
H NMR (CDCl3):  (ppm) 7.96 (2H, d, J = 8.63 Hz, Ph), 7.46 (2H, d, J = 8.63 Hz, 
Ph), 7.33-7.26 (4H, m, Ph), 3.96 (2H, m, CH2NCH2), 3.41 (2H, m, CH2NCH2), 2.69 (2H, m, 
CH2N(CH3)CH2), 2.49 (2H, m, CH2N(CH3)CH2), 2.33 (3H, s, NCH3), 1.32 (3H, s, CH3). 
13
C NMR 
(CDCl3):  (ppm) 164.75, 161.77, 149.33, 138.49, 138.20, 133.41, 131.77, 129.53, 128.63, 120.12, 
102.74, 55.85, 55.66, 55.17, 51.21, 45.81, 15.78. MS: m/z  429-431 (M+1)
+
; 451-453 (M+Na)
+
; 
881-879 (2M+Na)
+
. Anal. for C22H22Cl2N4O Calcd.%: C, 61.54; H, 5.16; N, 13.05; Found: C, 
61.68; H, 5.18; N, 13.10. 
5g: Yield: 50 %. 
1
H NMR (CDCl3):  (ppm) 7.94 (2H, d, J = 8.50 Hz, Ph), 7.48 (2H, d, J = 8.50 Hz, 
Ph), 7.32-7.26 (4H, m, Ph), 4.00 (2H, m, CH2OCH2), 3.95 (2H, m, CH2OCH2), 3.73 (2H, m, 
CH2NCH2), 3.37 (2H, m, CH2NCH2), 1.34 (3H, s, CH3). 
13
C NMR (CDCl3):  (ppm) 164.77, 
161.65, 149.34, 138.72, 138.05, 132.94, 131.83, 129.67, 128.88, 128.63, 120.21, 102.82, 67.59, 
67.40, 55.66, 51.79, 15.76. MS: m/z  416-418 (M+1)
+
; 438-440 (M+Na)
+
; 855-853 (2M+Na)
+
. 
Anal. for C21H19Cl2N3O2 Calcd.%: C, 60.59; H, 4.60; N, 10.09; Found: C, 60.83; H, 4.62; N, 10.13. 
5h: Yield: 26 %. 
1
H NMR (CDCl3):  (ppm) 7.99 (2H, d, J = 8.50 Hz, Ph), 7.47 (2H, d, J = 8.50 Hz, 
Ph), 7.34-7.24 (4H, m, Ph), 3.57 (3H, s, CH3NCH3), 3.07 (3H, s, CH3NCH3), 1.35 (3H, s, CH3). 
13
C 
NMR (CDCl3):  (ppm)  165.99, 161.90, 148.91, 138.49, 138.27, 133.23, 131.92, 129.41, 128.63, 
128.56, 120.08, 102.18, 46.75, 43.58, 15.62. MS: m/z  374-376 (M+1)
+
; 396-398 (M+Na)
+
; 412-
414 (M+K)
+
. Anal. for C19H17Cl2N3O  Calcd.%: C, 60.97; H, 4.58; N, 11.23; Found: C, 61.15; H, 
4.59; N, 11.26. 
5i: Yield: 55%. 
1
H NMR (CDCl3):  (ppm) 8.02 (2H, d, J = 8.53 Hz, Ph), 7.51 (2H, d, J = 8.53 Hz, 
Ph), 7.39 (2H, d, J = 8.53 Hz, Ph), 7.33 (2H, d, J = 8.53 Hz, Ph), 3.95 (2H, m, CH2NCH2), 3.40 
(2H, m, CH2NCH2), 1.88-1.74 (6H, m, CH2CH2CH2), 1.38 (3H, s, CH3).
 13
C-NMR (CDCl3): δ 
(ppm) 165.18, 161.80, 149.39, 138.45, 133.95, 131.55, 129.23, 128.82, 128.44, 119.89, 102.56, 
56.54, 52.50, 29.69, 27.46, 27.24, 23.54. MS: m/z  414-416 (M+1)
+
. Anal. for C22H21Cl2N3O 
Calcd.%: C, 63.77; H, 5.11; N, 10,14; Found: C, 62.37; H, 5.13; N, 10.19. 
5j: Yield: 56%. 
1
H NMR (CDCl3):  (ppm) 7.99 (2H, d, J = 8.85 Hz, Ph), 7.46 (2H, d, J = 8.83 Hz, 
Ph), 7.36 (2H, d, J = 8.63 Hz, Ph), 7.28 (2H, d, J = 8.63 Hz, Ph), 3.95 (2H, m, CH2NCH2), 3.48 
(1H, m, CH2NCH2), 3.23 (1H, m, CH2NCH2), 1.87 (4H, m, CH2CH(CH3)CH2), 1.49-1.46 (1H, m, 
CHCH3), 1.33 (3H, s, CH3), 1.01 (3H, d, J = 5.76 Hz, CH3).
 13
C-NMR (CDCl3):  (ppm) 165.18, 
161.82, 149.36, 138.34, 133.37, 129.95, 129.18, 128.47, 120.01, 102.63, 55.65, 51.83, 35.39, 29.86, 
21.35, 15.67. MS: m/z 428-430 (M+1)
+
; 450-452 (M+Na)
+
. Anal. for C23H24Cl2N3O Calcd.%: C, 
64.49; H, 5.41; N, 9.81; Found: C, 64.37; H, 5.35; N, 9.97. 
5k: Yield: 56 %. 
1
H NMR (CDCl3): δ (ppm) 7.97 (2H, d, J = 8.73 Hz, Ph), 7.46 (2H, d, J = 8.46 Hz, 
Ph), 7.36-7.30 (4H, m, Ph), 3.56 (3H, s, N-CH3), 3.38-3.34 (2H, m, CH3CH2CH2NCH3), 1.69-1.66 
(2H, m, CH3CH2CH2), 1.36 (3H, s, CH3), 0.81 (3H, t, J = 7.32, CH2CH3).
 13
C-NMR (CDCl3): δ 
(ppm) 165.55, 161.74, 152.73, 148.84, 138.22, 133.74, 131.87, 129.37, 128.49, 127.95, 119.96, 
102.74, 60.20, 57.54, 44.11, 40.99, 29.64, 21.94, 21.24, 15.66, 11.13, 10.47. MS: m/z 402-404 
(M+1)
+
; 424-426 (M+Na)
+
. Anal. for C21H21Cl2N3O Calcd.%: C, 62.69; H, 5.26; N, 10.44; Found: 
C, 62.71; H, 5.30; N, 10.47. 
 
5.4. Synthesis of aldehyde 8. 
To a stirred solution of compound 6 (1equiv/mol.) in DMF, 0.7 eq./mol of POCl3 and 2 eq./mol of 
DMF were added. The mixtures was heated at 80 °C for 2 h. After cooling, distilled H2O was added 
and the resulting solution was stirred for 48 h. The desisered product 8 was obtained as a yellow 
precipitate which was separated by filtration and used in the next step without any further 
purification. 
8: Yield: 92%. 
1
H NMR (CDCl3): δ (ppm) 10.26 (1H, bs, OH), 9.33 (1H, s, CHO), 7.67 (2H, bd, 
Ph), 7.31 (2H, bd, Ph), 2.34 (3H, s, CH3).
 13
C-NMR (CDCl3): δ (ppm) 159.60, 149.56, 135.30, 
132.07, 129.45, 128.93, 128.32, 121.86, 105.99, 13.12. MS: m/z 235 [M-H]
-
. Anal. for 
C11H9ClN2O2 Calcd.%: C, 55.83; H, 3.83; N, 11.84; Found: C, 56.01; H, 4.03; N, 12.04. 
 
5.5. Synthesis of pyrazolones 9a–g. 
Compound 8 (0.42 mmol, 1 eq./mol) and the appropriate amine (4 eq./ mol) were irradiated under 
microwave at 100 ° C for 5 min. The crude products 9a-g were then directly crystallized using 
AcOEt 100%. 
9a: Yield: 70%. 
1
H NMR (CDCl3): δ (ppm) 7.95 (2H, d, J = 8.30 Hz, Ph), 7.34-7.27 (4H, m, Ph), 
7.04 (1H, s, C=CH-piperazine), 6.96 (2H, d, J = 8.32 Hz, Ph), 4.93 (2H, m, CH2NCH2), 3.78 (2H, 
m, CH2NCH2), 3.38 (4H, m, CH2N(Ph)CH2), 2.22 (3H, s, CH3).
 13
C-NMR (CDCl3): δ (ppm) 
162.25, 150.82, 150.26, 149.35, 138.06, 129.48, 129.44, 129.40, 129.35, 128.99, 128.59, 128.55, 
121.16, 121.12, 120.40, 120.36, 116.92, 116.87, 99.46, 56.29, 51.45, 50.70, 50.64, 50.60, 49.82, 
13.56. MS: m/z 381 (M+1)
+
. Anal. for C21H21ClN4O Calcd.%: C, 66.22; H, 5.56; N, 14.71; Found: 
C, 66.34; H, 5.71; N, 14.83. 
9b: Yield: 60%. 
1
H NMR (CDCl3): δ (ppm) 7.94 (2H, d, J = 7.18 Hz, Ph), 7.29 (2H, d, J = 7.18 Hz, 
Ph), 6.93 (1H, s, C=CH-piperazine), 4.74 (2H, m, CH2NCH2), 3.58 (2H, s, CH2NCH2), 2.58 (4H, m, 
CH2NCH2), 2.33 (3H, s, NCH3), 2.16 (3H, s, CH3).
 13
C-NMR (CDCl3): δ (ppm) 162.03, 150.79, 
138.17, 128.82, 128.49, 128.37, 99.13, 56.38, 55.38, 54.97, 51.53, 45.65, 13.43. MS: m/z 319 
(M+1)
+
. Anal. for C16H19ClN4O Calcd.%: C, 60.28; H, 6.01; N, 17.57; Found: C, 60.33; H, 5.07; N, 
17.63. 
9c: Yield: 53%. 
1
H NMR (CDCl3): δ (ppm) 7.93 (2H, d, J = 7.64 Hz, Ph), 7.31 (2H, d, J = 7.64 Hz, 
Ph), 6.94 (1H, s, C=CH-morpholine), 4.80 (2H, m, CH2NCH2), 3.86 (4H, m, CH2OCH2), 3.58 (2H, 
m, CH2NCH2), 2.19 (3H, s, CH3).
 13
C-NMR (CDCl3): δ (ppm) 161.74, 148.29, 138.04, 128.52, 
128.47, 120.37, 67.07, 56.15, 52.34, 13.41. MS: m/z 312 (M+1)
+
; 334 (M+Na)
+
. Anal. for 
C15H16ClN3O2 Calcd.%: C, 58.92; H, 5.27; N, 13.74; Found: C, 59.02; H, 5.35; N, 14.02. 
9d: Yield: 30%. 
1
H NMR (CDCl3): δ (ppm) 7.93 (2H, d, J = 8.48 Hz, Ph), 7.33 (2H, d, J = 8.48 Hz, 
Ph), 7.01 (1H, s, C=CH-piperazine, 4.78 (2H, m, CH2NCH2), 3.83 (2H, m, CH2NCH2), 3.70 (2H, 
m, CH2N(CH3)CH2), 3.59 (2H, m, CH2N(CH3)CH2), 2.21 (3H, s, CH3), 2.17 (3H, s, COCH3).
 13
C-
NMR (CDCl3): δ (ppm) 152.75, 149.40, 137.87, 129.19, 128.56, 120.39, 55.79, 51.49, 41.86, 21.21, 
13.43. MS: m/z 369 (M+Na)
+
. Anal for C17H19ClN4O2 Calcd.%: C, 58.87; H, 5.52; N, 16.15; 
Found: C, 58.93; H, 5.54; N, 16.32. 
9e: Yield: 48%. 
1
H NMR (CDCl3): δ (ppm) 11.42 (1H, bs, NH), 8.0 (2H, d, J = 8.16 Hz, Ph), 7.89 
(1H, s, CH=NHPh), 7.41 (2H, d, J = 7.18 Hz, Ph), 7.35 (2H, d, J = 8.16 Hz, Ph), 7.25-7.20 (3H, m, 
Ph), 2.29 (3H, s, CH3).
 13
C-NMR (CDCl3): δ (ppm) 161.15, 148.22, 142.85, 138.47, 137.57, 130.06, 
129.14, 128.72, 125.84, 119.79, 117.31, 102.94, 12.60. MS: m/z 306 (M+1)
+
; 328 (M+Na)
+
. Anal. 
for C17H16ClN3O Calcd.%: C, 65.07; H, 5.14; N, 13.39; Found: C, 66.01; H, 5.24; N, 13.77. 
9f: Yield: 37%. 
1
H NMR (CDCl3): δ (ppm) 7.93 (2H, d, J = 8.10 Hz, Ph), 7.31 (2H, d, J = 8.10 Hz, 
Ph), 6.96 (1H, s, C=CH-piperazine, 4.78 (2H, m, CH2NCH2), 4.78 (2H, m, CH2NCH2), 3.68 (2H, 
m, CH2NCH2), 3.64 (2H, m, CH2OH), 2.74 (4H, m, CH2N(CH2CH2OH)CH2), 2.64 (2H, m, NCH2 
CH2OH), 2.19 (3H, s, CH3).
 13
C-NMR (CDCl3): δ (ppm) 162.04, 150.75, 149.41, 130.08, 128.97, 
128.56, 120.40, 59.17, 58.08, 56.39, 53.43, 53.0, 51.58, 13.42. MS: m/z 349 (M+1)
+
. Anal. for 
C17H21ClN4O2 Calcd.%: C, 58.53; H, 6.07; N, 16.06; Found: C, 58.62; H, 6.11; N, 16.12. 
9g: Yield: 74%. 
1
H NMR (CDCl3): δ (ppm) 7.93 (2H, d, J = 8.56 Hz, Ph), 7.50 (1H, s, H3-Furane), 
7.31 (2H, d, J = 8.56 Hz, Ph), 7.09 (1H, s, C=CH-Piperazine), 6.98 (1H, s, H4-Furane), 6.51 (1H, s, 
H5-Furane), 4.80 (2H, m, CH2NCH2), 4.05 (2H, m, CH2N(CO)CH2), 3.96 (2H, m, CH2N(CO)CH2), 
3.62 (2H, m, CH2NCH2), 2.19 (3H, s, CH3).
 13
C-NMR (CDCl3): δ (ppm) 163.02, 150.73, 149.44, 
147.30, 144.22, 137.96, 129.10, 128.52, 120.35, 117.71, 111.65, 100.04, 55.92, 51.81, 29.66, 13.42. 
MS: m/z 399 (M+1)
+
. Anal. for. C20H19ClN4O3 Calcd.%: C, 60.23; H, 4.80; N, 14.05; Found: C, 
60.35; H, 5.12; N, 14.09. 
 
6. Microbiological assays 
 
6.1. Mycobacterial strain 
M. tuberculosis H37Rv ATCC 27294 was used in this study. It was maintained on Löwenstein-
Jensen (bioMérieux, Marcy l’Étoile, France) agar slants until needed. 
 
6.2. Antimicrobial susceptibility testing 
MICs were determined by a standard twofold agar dilution method. Briefly, 1 mL of Middlebrook 
7H11 agar (Becton Dickinson BBL, Sparks, MD) supplemented with 10% oleic acid-albumin-
dextrose-catalase enrichment containing the testing compounds in 24-multiwell plates at 
concentrations ranging between 0.0312 and 64 μg/mL was inoculated with 10 μL of a suspension 
containing M. tuberculosis H37Rv 1.5 × 10
5
 cfu/mL grown on Middlebrook 7H9 broth (Difco 
Laboratories, Detroit, MI) supplemented with 10% albumin-dextrose-catalase enrichment. Final 
inoculum was 1.5 × 10
3
 per well and was obtained as described previously.
8
 Plates were incubated 
for 21–28 days and MICs were read as minimal concentrations of compounds completely inhibiting 
visible growth of mycobacteria. 
 
7. Computational details 
Computational analysis was performed by means of the Catalyst software package, version 4.10, 
following a protocol previously described.
5
 
 
8. Acknowledgements 
Financial support from the Italian Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN 
2005037820) is gratefully acknowledged. CARIPLO (Grant Rif. 2006.0880/10.8485 Bando 2006) 
is gratefully acknowledged. We thank Asinex for partial financial support for this work. 
 
 
9. References 
 
1. Brock, T. D. Robert Koch: A Life in Medicine and Bacteriology; Science Tech. Publishers: 
Madison, WI, 1998. 
2. World Health Organization, 2008, 
http://www.who.int/tb/publications/global_report/2008/pdf/summary.pdf 
3. (a) Janin, Y. L. Bioorg. Med. Chem. 2007, 15, 2479; (b) Gutierrez-Lugo, M. T.; Bewley, C. 
J. Med. Chem. 2008, 51, 2606-2612. (c) 
http://www.who.int/tb/challenges/xdr/xdr_mdr_factsheet_2007_en.pdf  
4. Manetti, F.; Magnani, M.; Castagnolo, D.; Passalacqua, L.; Botta, M.; Corelli, F.; Saddi, M.; 
Deidda, D.; De Logu, A. ChemMedChem 2006, 1, 973. 
5. Castagnolo, D.; De Logu, A.; Radi, M.; Bechi, B.; Manetti, F.; Magnani, M.; Supino, S.; 
Meleddu, R.; Chisu, L.; Botta, M. Bioorg. Med. Chem. 2008, 16, 8587-8591.  
6. Holzer, W.; Kautsch, C.; Laggner, C.; Claramunt, R. M.; Pérez-Torralba, M.; Alkorta, I.; 
Elguero, J. Tetrahedron 2004, 60, 6791. 
7. (a) Biava, M.; Porretta, G. C.; Poce, G.; De Logu, A.; Saddi, M.; Meleddu, R.; Manetti, F.; 
De Rossi, E.; Botta, M. J. Med. Chem. 2008, 51, 3644-3648. (b) Biava, M.; Porretta, G. C.; 
Poce, G.; Supino, S.; Deidda, D.; Pompei, R.; Molicotti, P.; Manetti, F.; Botta, M. J. Med. 
Chem. 2006, 49, 4946-4952. (c) Biava, M. Curr. Med. Chem. 2002, 9, 1859-1869. (d) 
Deidda, D.; Lampis, G.; Fioravanti, R.; Biava, M.; Porretta, G. C.; Zanetti, S.; Pompei, R. 
Antimicrob. Agents Chemother. 1998, 42, 3035-3037. 
8. De Logu, A.; Onnis, V.; Saddi, B.; Congiu, C.; Schivo, M. L.; Cocco, M. T. J. Antimicrob. 
Chemother. 2002, 49, 275. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
